Around the world, life-saving drugs remain too expensive for too many. BiosanaPharma is working to change that. The company manufactures biosimilars—a pharmaceutical product that is almost identical to a product that is manufactured by a different company. By creating competition, biosimilars can make these medicines available to the public more affordably. The process of continuous biomanufacturing, however, involves a dizzying and intricate array of equipment.
That’s why BiosanaPharma uses CONNECT data services to aggregate data from all its equipment and share it with trusted partners. Together, with the right tools, and right partners, BiosanaPharma is optimizing the biomanufacturing process and producing essential drugs at an affordable price.
“The future of biopharma is ‘lights out’ continuous end-to-end processing. The cost of goods of antibodies will decrease by a factor 10 in the next decade because of innovation.”
- Maarten Pennings,
CTO, BiosanaPharma
Challenges
- Massive amount of process parameters and attributes at different scales and sites
- Data stored across multiple databases and devices
- Lacked real-time scale-up performance monitoring and failure mode and excursion monitoring
Solution
- Used CONNECT data services to aggregate data from various sources at the development laboratory and the manufacturing site, ensuring comparability, data integrity, and contextualization
Result
- Simple, secure data sharing provides:
- A single point-of-truth, offering contextualized real-time and historical data
- Efficient real-time visualization and offline analysis
- Process parameters and quality attributes and excursions using SIMCA-online MVDA models
Related success stories
Stay in the know: Keep up to date on the latest happenings around the industry.
